AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus

European Journal of Pharmacology

Volumn 572, Issue 2-3, 2007, Pages 129-137

  Li, Zhu ^a   Bonhaus, Douglas W ^a   Huang, Mei ^a   Prus, Adam J ^a   Dai, Jin ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AC260584; Acetylcholine; Cognition; Dopamine; Microdialysis; Muscarinic

Indexed keywords

4 [3 (4 BUTYLPIPERIDIN 1 YL) PROPYL] 7 FLUORO 4H BENZO[1,4] OXAZIN 3 ONE; AC 260584; ACETYLCHOLINE; DOPAMINE; MUSCARINIC M1 RECEPTOR AGONIST; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RISPERIDONE; TELENZEPINE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG DOSE INCREASE; DRUG POTENTIATION; HIPPOCAMPUS; MALE; MICRODIALYSIS; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ACETYLCHOLINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOXAZINES; DOPAMINE; DRUG SYNERGISM; HIPPOCAMPUS; MALE; MICRODIALYSIS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; RISPERIDONE;

EID: 34548797583     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.06.025     Document Type: Article

References (69)

1. Bodick N.C., Offen W.W., Shannon H.E., Satterwhite J., Lucas R., van Lier R., and Paul S.M. The selective muscarinic receptor agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 11 Suppl 4 (1997) S16-S22
2. Bolam J.P., Francis C.M., and Henderson Z. Cholinergic input to dopaminergic neurons in the substantia nigra: a double immunocytochemical study. Neuroscience 41 (1991) 483-494
3. Brashear H.R., Zaborszky L., and Heimer L. Distribution of GABAergic and cholinergic neurons in the rat diagonal band. Neuroscience 17 (1986) 439-451
4. Bymaster F.P., Heath I., Hendrix J.C., and Shannon H.E. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J. Pharmacol. Exp. Ther. 267 (1993) 16-24
5. Bymaster F.P., Felder C., Ahmed S., and McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 163-181
6. Carnes K.M., Fuller T.A., and Price J.L. Sources of presumptive glutamatergic/aspartatergic afferents to the magnocellular basal forebrain in the rat. J. Comp. Neurol. 302 (1990) 824-852
7. Casamenti F., Deffenu G., Abbamondi A.L., and Pepeu G. Changes in cortical acetylcholine output induced by modulation of the nucleus basalis. Brain Res. Bull. 16 (1986) 689-695
8. Charpantier E., Barneoud P., Moser P., Besnard F., and Sgard F. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. NeuroReport 9 (1998) 3097-3101
9. 1A receptor agonism. Brain Res. 1023 (2004) 54-63
10. Crook J.M., Tomaskovic-Crook E., Copolov D.L., and Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am. J. Psychiatry 158 (2001) 918-925
11. Cummings J.L., and Benson D.F. The role of the nucleus basalis of Meynert in dementia: review and reconsideration. Alzheimer Dis. Assoc. Disord. 1 (1987) 128-155
12. Davis K.L., Hollister L.E., Berger P.A., and Barchas J.D. Cholinergic imbalance hypotheses of psychoses and movement disorders: strategies for evaluation. Psychopharmacol. Commun. 1 (1975) 533-543
13. Dunnett S.B., Everitt B.J., and Robbins T.W. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. Trends Neurosci. 14 (1991) 494-501
14. Fink-Jensen A., Kristensen P., Shannon H.E., Calligaro D.O., Delapp N.W., Whitesitt C., Ward J.S., Thomsen C., Rasmusseen T., Sheardown M.J., Jeppesen L., Sauerberg P., and Bymaster F.P. Muscarinic receptor agonists exhibit functional dopamine antagonism in unilaterally 8-hydroxy-2-(din-propylamino)tetralin-lesioned rats. NeuroReport 9 (1998) 3481-3486
15. Frazier J.A., Cohen L.G., Jacobsen L., Grothe D., Flood J., Baldessarini R.J., Piscitelli S., Kim G.S., and Rapoport J.L. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J. Clin. Psychopharmacol. 23 (2003) 87-91
16. Freedman R., Adams C.E., and Leonard S. The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J. Chem. Neuroanat. 20 (2000) 299-306
17. Gould E., Woolf N.J., and Butcher L.L. Cholinergic projections to the substantia nigra from the pedunculopontine and laterodorsal tegmental nuclei. Neuroscience 28 (1989) 611-623
18. 1 muscarinic acetylcholine receptor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 15312-15317
19. Geyer M.A., and Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 (2003) 1071-1079
20. Geyer M.A., and Heinssen R. New approaches to measurement and treatment research to improve cognition in schizophrenia. Schizophr. Bull. 31 (2005) 806-809
21. Gronier B., and Rasmussen K. Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic receptors: an in vivo electrophysiological study in the rat. Br. J. Pharmacol. 124 (1998) 455-464
22. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., and Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical dopamine release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76 (2001) 1521-1531
23. Ichikawa J., Dai J., and Meltzer H.Y. 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res. 939 (2002) 34-42
24. Ichikawa J., Dai J., O'Laughlin I.A., Fowler W.L., and Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26 (2002) 325-339
25. Ichikawa J., Chung Y.C., Li Z., Huang M., and Meltzer H. Telenzepine, a muscarinic M1/4 receptor antagonist, blocks the ability of clozapine and risperidone to increase cortical acetylcholine and dopamine release: role of M1/4 agonism in schizophrenia. Abstract Viewer/Itinerary Planner (2004)
26. Imperato A., and Angelucci L. The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats. Psychopharmacol. Bull. 25 (1989) 383-389
27. Jones C.K., Eberle E.L., Shaw D.B., McKinzie D.L., and Shannon H.E. Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J. Pharmacol. Exp. Ther. 312 (2005) 1055-1063
28. Kawashima K., Sato A., Yoshizawa M., Fujii T., Fujimoto K., and Suzuki T. Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn-Schmiedeberg's Arch Pharmacol. 350 (1994) 523-528
29. Kitai S.T., Shepard P.D., Callaway J.C., and Scroggs R. Afferent modulation of dopamine neuron firing patterns. Curr. Opin. Neurobiol. 9 (1999) 690-697
30. Krugel U., Bigl V., Eschrich K., and Bigl M. Deafferentation of the septo-hippocampal pathway in rats as a model of the metabolic events in Alzheimer's disease. Int. J. Dev. Neurosci. 19 (2001) 263-277
31. Kuroki T., Meltzer H.Y., and Icikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288 (1999) 774-781
32. Kurosawa M., Sato A., and Sato Y. Stimulation of the nucleus basalis of Meynert increases acetylcholine release in the cerebral cortex in rats. Neurosci. Lett. 98 (1989) 45-50
33. Levin E.D., McGurk S.R., Rose J.E., and Butcher L.L. Cholinergic-dopaminergic interactions in cognitive performance. Behav. Neural Biol. 54 (1990) 271-499
34. Li Z., Ichikawa J., Dai J., and Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 493 (2004) 75-83
35. 1 muscarinic receptors. Neuropsychopharmacology 30 (2005) 1986-1995
36. 2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl) 183 (2005) 144-153
37. 6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res. 1134 (2007) 70-78
38. Maura G., and Raiteri M. Cholinergic terminals in rat hippocampus possess 5-HT1B receptors mediating inhibition of acetylcholine release. Eur. J. Pharmacol. 129 (1986) 333-337
39. Mauri M.C., Volonteri L.S., Dell'Osso B., Regispani F., Papa P., Baldi M., and Bareggi S.R. Predictors of clinical outcome in schizophrenic patients responding to clozapine. J. Clin. Psychopharmacol. 23 (2003) 660-664
40. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognition in schizophrenia. Schizophr. Bull. 25 (1999) 233-256
41. 1 muscarinic acetylcholine receptor. J. Neurosci. 21 (2001) 5239-5250
42. Moghaddam B., and Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54 (1990) 1755-1760
43. Murakami Y., Matsumoto K., Ohta H., and Watanabe H. Effects of oxotremorine and pilocarpine on striatal acetylcholine release as studied by brain dialysis in anesthetized rats. Gen. Pharmacol. 27 (1996) 833-836
44. Mirza N.R., Peters D., and Sparks R.G. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 9 (2003) 159-186
45. Ogane N., Takada Y., Iga Y., Kawanishi G., and Mizobe F. Effects of a M1 muscarinic receptor agonist on the central cholinergic system, evaluated by brain microdialysis. Neurosci. Lett. 114 (1990) 95-100
46. 1 receptor agonist, AF102B. Eur. J. Pharmacol. 155 (1988) 77-84
47. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1998), Academic Press, New York
48. Perry E.K., and Perry R.H. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn. 28 (1995) 240-258
49. Perry E., Walker M., Grace J., and Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci. 22 (1999) 273-280
50. Rasmusson D.D., Clow K., and Szerb J.C. Frequency-dependent increase in cortical acetylcholine release evoked by stimulation of the nucleus basalis magnocellularis in the rat. Brain Res. 594 (1992) 150-154
51. Sarter M., and Bruno J.P. Cortical acetylcholine, reality distortion, schizophrenia, and Lewy Body dementia: too much or too little cortical acetylcholine?. Brain Cogn. 38 (1998) 297-316
52. Shannon H.E., Bymaster F.P., Calligaro D.O., Greenwood B., Mitch C.H., Sawyer B.D., Ward J.S., Wong D.T., Olesen P.H., and Sheardown M.J. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for muscarinic M1 receptors. J. Pharmacol. Exp. Ther. 269 (1994) 271-281
53. Shannon H.E., Rasmussen K., Bymaster F.P., Hart J.C., Peters S.C., Swedberg M.D., Jeppesen L., Sheardown M.J., Sauerberg P., and Fink-Jensen A. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr. Res. 42 (2000) 249-259
54. Shirazi-Southall S., Rodriguez D.E., and Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26 (2002) 583-594
55. Spalding T.A., Ma J.N., Ott T.R., Friberg M., Bajpai A., Bradley S.R., Davis R.E., Brann M.R., and Burstein E.S. Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Mol. Pharmacol. 70 (2006) 1974-1983
56. Stanhope K.J., Mirza N.R., Bickerdike M.J., Bright J.L., Harrington N.R., Hesselink M.B., Kennett G.A., Lightowler S., Sheardown M.J., Syed R., Upton R.L., Wadsworth G., Weiss S.M., and Wyatt A. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J. Pharmacol. Exp. Ther. 299 (2001) 782-792
57. Sur C., Mallorga P.J., Wittmann M., Jacobson M.A., Pascarella D., Williams J.B., Brandish P.E., Pettibone D.J., Scolnick E.M., and Conn P.J. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13674-13679
58. Suzuki T., Hirooka K., Kanda K., Uesaka H., Hirooka H., and Furusawa K. Characterization of the neurochemical effects of N-[2-(1-azabicyclo[3,3,0]octan-5-yl)ethyl]2-nitroaniline fumarate (SK-946) as a cognition activator. Biol. Pharm. Bull. 21 (1998) 704-709
59. Svensson A.L., Zhang X., and Nordberg A. Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors. Brain Res. 726 (1996) 207-212
60. Tandon R., and Greden J.F. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch. Gen. Psychiatry 46 (1989) 745-753
61. Tzschentke T.M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog. Neurobiol. 63 (2001) 241-320
62. Weiner D.M., Levey A.I., and Brann M.R. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 7050-7054
63. Weiner D.M., Meltzer H.Y., Veinbergs I., Donohue E.M., Spalding T.A., Smith T.T., Mohell N., Harvey S.C., Lameh J., Nash N., Vanover K.E., Olsson R., Jayathilake K., Lee M., Levey A.I., Hacksell U., Burstein E.S., Davis R.E., and Brann M.R. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 177 (2004) 207-216
64. Winkler J., Suhr S.T., Gage F.H., Thal L.J., and Fisher L.J. Essential role of neocortical acetylcholine in spatial memory. Nature 375 (1995) 484-487
65. Winn P., Brown V.J., and Inglis W.L. On the relationships between the striatum and the pedunculopontine tegmental nucleus. Crit. Rev. Neurobiol. 11 (1997) 241-261
66. Woolf N., and Butcher L. Cholinergic systems: synopsis of anatomy and overview of physiology and pathology. The Biological Substrates of Alzheimer's Disease (1989), Academic Press, New York 73-86
67. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 1-16
68. Yeomans J.S. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 12 (1995) 3-16
69. Zaborszky L., Cullinan W.E., and Braun A. Afferents to basal forebrain cholinergic projection neurons: an update. Adv. Exp. Med. Biol. 295 (1991) 43-100